trending Market Intelligence /marketintelligence/en/news-insights/trending/ZV-phN77WFr0M0xOL92FDw2 content esgSubNav
In This List

Protagonist Therapeutics plans common stock offering

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Protagonist Therapeutics plans common stock offering

Protagonist Therapeutics Inc. plans to sell its common stock in an underwritten public offering.

The company also plans to grant the underwriters an option to buy up to an additional 15% of the number of shares sold in the offering.

Protagonist plans to use the net proceeds to fund clinical research and development of the company's three therapeutic candidates — PTG-100, PTG-200, and PTG-300 — including the completion of ongoing clinical trials, discovery programs and platform development, and for working capital and general corporate purposes.

Leerink Partners LLC and Barclays Capital Inc. are acting as joint lead book-running managers, BMO Capital Markets Corp. and Stifel Nicolaus & Co. are acting as passive joint book-running managers, and BTIG and Nomura are acting as co-lead managers for the offering.